p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis
Open Access
- 18 February 2013
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 210 (3) , 581-603
Abstract
The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly characterized. Mutations in TP53 occur infrequently, yet the TP53 apoptotic pathway is often abrogated. This may result from alterations in TP53 family members, including the TP53 homologue TP63. Here we demonstrate that TP63 has an antiapoptotic role in melanoma and is responsible for mediating chemoresistance. Although p63 was not expressed in primary melanocytes, up-regulation of p63 mRNA and protein was observed in melanoma cell lines and clinical samples, providing the first evidence of significant p63 expression in this lineage. Upon genotoxic stress, endogenous p63 isoforms were stabilized in both nuclear and mitochondrial subcellular compartments. Our data provide evidence of a physiological interaction between p63 with p53 whereby translocation of p63 to the mitochondria occurred through a codependent process with p53, whereas accumulation of p53 in the nucleus was prevented by p63. Using RNA interference technology, both isoforms of p63 (TA and ΔNp63) were demonstrated to confer chemoresistance, revealing a novel oncogenic role for p63 in melanoma cells. Furthermore, expression of p63 in both primary and metastatic melanoma clinical samples significantly correlated with melanoma-specific deaths in these patients. Ultimately, these observations provide a possible explanation for abrogation of the p53-mediated apoptotic pathway in melanoma, implicating novel approaches aimed at sensitizing melanoma to therapeutic agents.Keywords
This publication has 130 references indexed in Scilit:
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cellsCell Death & Disease, 2011
- E2F1-dependent oncogenic addiction of melanoma cells to MDM2Oncogene, 2011
- Identification and functional characterization of two new transcriptional variants of the human p63 geneNucleic Acids Research, 2009
- MDM4 (MDMX) localizes at the mitochondria and facilitates the p53‐mediated intrinsic‐apoptotic pathwayThe EMBO Journal, 2009
- Aberrant Cytoplasmic Expression of p63 and Prostate Cancer MortalityCancer Epidemiology, Biomarkers & Prevention, 2009
- ΔNp63 expression is associated with poor survival in ovarian cancerAnnals of Oncology, 2007
- Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expressionCancer Chemotherapy and Pharmacology, 2007
- Monoubiquitylation promotes mitochondrial p53 translocationThe EMBO Journal, 2007
- TAp63α induces apoptosis by activating signaling via death receptors and mitochondriaThe EMBO Journal, 2005
- p63 and p73 are required for p53-dependent apoptosis in response to DNA damageNature, 2002